11 March 2025 - CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian market for over 10 years.

Celltrion announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry starting 1 April 2025, following approval of the product name change by Health Canada.

Read Celltrion press release